Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study.

Ong KL, O'Connell R, Januszewski AS, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Scott RS, Taskinen MR, Waldman B, Colman PG, Best JD, Simes JR, Rye KA, Keech AC; FIELD study investigators.

Clin Chem. 2017 Jul;63(7):1261-1270. doi: 10.1373/clinchem.2016.270876. Epub 2017 Jun 12.

PMID:
28606915
2.

Erratum to: Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

d'Emden MC, Jenkins AJ, Li L, Zannino D, Mann KP, Best JD, Stuckey BG, Park K, Saltevo J, Keech AC; FIELD Study Investigators.

Diabetologia. 2015 Sep;58(9):2200. doi: 10.1007/s00125-015-3693-6. No abstract available.

PMID:
26186882
3.

Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study.

Ong KL, Januszewski AS, O'Connell R, Buizen L, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Scott RS, Taskinen MR, Rye KA, Keech AC; FIELD study investigators.

Diabetologia. 2015 Sep;58(9):2035-44. doi: 10.1007/s00125-015-3652-2. Epub 2015 Jun 9.

PMID:
26055067
4.

Serum 25-hydroxyvitamin D: a predictor of macrovascular and microvascular complications in patients with type 2 diabetes.

Herrmann M, Sullivan DR, Veillard AS, McCorquodale T, Straub IR, Scott R, Laakso M, Topliss D, Jenkins AJ, Blankenberg S, Burton A, Keech AC; FIELD Study Investigators.

Diabetes Care. 2015 Mar;38(3):521-8. doi: 10.2337/dc14-0180. Epub 2014 Dec 18.

PMID:
25524951
5.

Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

d'Emden MC, Jenkins AJ, Li L, Zannino D, Mann KP, Best JD, Stuckey BG, Park K, Saltevo J, Keech AC; FIELD Study Investigators.

Diabetologia. 2014 Nov;57(11):2296-303. doi: 10.1007/s00125-014-3344-3. Epub 2014 Aug 23. Erratum in: Diabetologia. 2015 Sep;58(9):2200.

PMID:
25149070
6.

HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes.

Waldman B, Jenkins AJ, Davis TM, Taskinen MR, Scott R, O'Connell RL, Gebski VJ, Ng MK, Keech AC; FIELD Study Investigators.

Diabetes Care. 2014 Aug;37(8):2351-8. doi: 10.2337/dc13-2738. Epub 2014 May 7.

PMID:
24804699
7.

Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Chan KH, O'Connell RL, Sullivan DR, Hoffmann LS, Rajamani K, Whiting M, Donoghoe MW, Vanhala M, Hamer A, Yu B, Stocker R, Ng MK, Keech AC; FIELD Study Investigators.

Diabetologia. 2013 Apr;56(4):724-36. doi: 10.1007/s00125-012-2818-4. Epub 2013 Jan 17.

PMID:
23322233
8.

Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes.

Ong KL, Rye KA, O'Connell R, Jenkins AJ, Brown C, Xu A, Sullivan DR, Barter PJ, Keech AC; FIELD study investigators.

J Clin Endocrinol Metab. 2012 Dec;97(12):4701-8. doi: 10.1210/jc.2012-2267. Epub 2012 Nov 8.

PMID:
23144467
9.

Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study.

Herrmann M, Whiting MJ, Veillard AS, Ehnholm C, Sullivan DR, Keech AC; FIELD study investigators.

Clin Chem Lab Med. 2012 Dec;50(12):2213-9.

PMID:
23093273
10.

Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Tonkin A, Hunt D, Voysey M, Kesäniemi A, Hamer A, Waites J, Mahar L, Mann S, Glasziou P, Forder P, Simes J, Keech AC; FIELD Study Investigators.

Am Heart J. 2012 Mar;163(3):508-14. doi: 10.1016/j.ahj.2011.12.004.

PMID:
22424024
11.

Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.

Ting RD, Keech AC, Drury PL, Donoghoe MW, Hedley J, Jenkins AJ, Davis TM, Lehto S, Celermajer D, Simes RJ, Rajamani K, Stanton K; FIELD Study Investigators.

Diabetes Care. 2012 Feb;35(2):218-25. doi: 10.2337/dc11-1109. Epub 2011 Dec 30.

12.

Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial.

Scott R, Donoghoe M, Watts GF, O'Brien R, Pardy C, Taskinen MR, Davis TM, Colman PG, Manning P, Fulcher G, Keech AC; FIELD Study Investigators.

Cardiovasc Diabetol. 2011 Nov 21;10:102. doi: 10.1186/1475-2840-10-102.

13.

Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study.

Sullivan D, Forder P, Simes J, Whiting M, Kritharides L, Merrifield A, Donoghoe M, Colman PG, Graham N, Haapamäki H, Keech A; FIELD Study Investigators.

Diabetes Res Clin Pract. 2011 Nov;94(2):284-90. doi: 10.1016/j.diabres.2011.07.028. Epub 2011 Aug 21.

PMID:
21862166
14.

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.

Taskinen MR, Barter PJ, Ehnholm C, Sullivan DR, Mann K, Simes J, Best JD, Hamwood S, Keech AC; FIELD study investigators.

Diabetologia. 2010 Sep;53(9):1846-55. doi: 10.1007/s00125-010-1806-9. Epub 2010 Jun 6.

PMID:
20526762
15.

A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials.

Simes J, Voysey M, O'Connell R, Glasziou P, Best JD, Scott R, Pardy C, Byth K, Sullivan DR, Ehnholm C, Keech A; FIELD Study Investigators.

PLoS One. 2010 Jan 8;5(1):e8580. doi: 10.1371/journal.pone.0008580. Erratum in: PLoS One. 2010;5(1). doi: 10.1371/annotation/54433693-04e0-4f30-9a99-38fe3c5bb16b.

16.

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.

Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, Laakso M, Baker JR, Keech AC; FIELD study investigators.

Lancet. 2009 May 23;373(9677):1780-8. doi: 10.1016/S0140-6736(09)60698-X.

17.

Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.

Taskinen MR, Sullivan DR, Ehnholm C, Whiting M, Zannino D, Simes RJ, Keech AC, Barter PJ; FIELD study investigators.

Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):950-5. doi: 10.1161/ATVBAHA.108.178228. Epub 2009 Mar 26.

18.

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d'Emden MC, Crimet DC, O'Connell RL, Colman PG; FIELD study investigators.

Lancet. 2007 Nov 17;370(9600):1687-97. Epub 2007 Nov 7.

PMID:
17988728
19.

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators.

Lancet. 2005 Nov 26;366(9500):1849-61. Erratum in: Lancet. 2006 Oct 21;368(9545):1415. Lancet. 2006 Oct 21;368(9545):1420.

PMID:
16310551
20.

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].

Scott R, Best J, Forder P, Taskinen MR, Simes J, Barter P, Keech A; FIELD Study Investigators.

Cardiovasc Diabetol. 2005 Aug 22;4:13.

Supplemental Content

Loading ...
Support Center